Home  >  News
Biotechnology + Font Resize -

Hetero launches biosimilar ‘Adalimumab’ in Indian market

Our Bureau, Mumbai
Wednesday, January 3, 2018, 12:50 Hrs  [IST]

Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs, has launched its fourth biosimilar drug ‘Adalimumab’ under the brand name ‘Mabura’ in India.

The product will be marketed and distributed by Hetero Healthcare in the country.

Mabura is an anti-inflammatory biologic medication specific for human tumour necrosis factor (TNF), indicated for the treatment of rheumatoid arthritis and other auto-immune disorders such as psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis etc.

Mabura will be available as a pre-filled syringe (PFS) of 40mg and is administered subcutaneously.

Hetero’s Mabura is the biosimilar version of AbbVie’s Humira. Adalimumab is the first fully human monoclonal antibody which was first approved by US FDA in 2002.

According to the company press release, the product will be manufactured at their dedicated state-of-the-art manufacturing facility for biologics, based at Hyderabad, India.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
duphat_150x60
IPJPI18_150x60en_2018
PHARMACONNECT_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |